Several studies have reported that CEACAM6 is overexpressed in numerous cancers, especially in NSCLC, colorectal carcinoma, and PDAC, and have explored various strategies targeting CEACAM6, including monoclonal antibodies, antibody–drug conjugates, chimeric antigen receptor (CAR) T-cells, and bispecific T cell engagers [3]. This evidence concerns the gene CEACAM6 and non-small cell lung carcinoma.